• Responsible for preclinical and Phase 1 clinical development of a small molecule to treat pulmonary artery hypertension • Filed IND and ran Phase 1 trial for C-122, an inhibitor of serotonin receptor 5-HTR2b

• Responsible for compound synthesis, screening, animal efficacy, toxicology, pharmacokinetics, and manufacturing in pursuit of novel therapies for rheumatoid arthritis, asthma, and pulmonary artery hypertension

• Responsible for invention and development of GlycoPEGylation®, a novel method to prolong plasma half life of glycoprotein biologics. • Responsible for directing 90 people (60 Horsham, PA; 30 San Diego, CA) including 28 doctoral level scientists. • Invented and developed c-GMP manufacturing processes for recombinant glycosyltransferases and N-pegylated CMP-sialic acid • IND submitted, conducted Ph 1 and Ph 2 trials for Glycopegylated® Erythropoietin. • Developed GlycoPEGylated recombinant Factor VIIa, partnered drug with Novo Nordisk.• Developed GlycoPEGylated® recombinant GCSF, partnered drug with BioGenerix.• Initiated technical development of recombinant glycosyltransferases and sugar nucleotides for remodeling of glycans to optimize performance of biologic drugs• Explored in vitro glycosylation of multiple glycoprotein drugs with industrial parters; signed R&D agreement with Wyeth.• Responsible for screening, synthesis, scale-up, animal efficacy, toxicology, c-GMP manufacturing, IND filings, and conduct of Phase 1 and Phase 2 trials for oligosaccharide inhibitors of bacterial adhesion intended for prevention of otitis media in infants (NE-1530) and Helicobacter pylori gastritis in adults (NE-0080).